BVS — Bioventus Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual income statement for Bioventus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	R2021 December 31st	R2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	340	321	431	512	512
Cost of Revenue
Gross Profit	249	234	303	331	328
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	312	296	421	679	594
Operating Profit	28.2	25.4	9.9	-167	-81.7
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	9.69	15.9	9.49	-189	-121
Provision for Income Taxes
Net Income After Taxes	8.11	14.7	11.5	-145	-121
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	6.85	16.4	19.4	-173	-171
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-0.659	4.38	19.4	-173	-171
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.166	0.207	0.615	0.098	-0.381
Dividends per Share